Publication | Closed Access

Economic Analysis of Decitabine Versus Best Supportive Care in the Treatment of Intermediate- and High-Risk Myelodysplastic Syndromes From a US Payer Perspective

Us Payer PerspectiveHealthcare ValueHealth PolicyHealth EconomicsHealth Care ReimbursementHigh-risk Myelodysplastic SyndromesEconomic AnalysisHealth Care CostHealth Care FinancePublic HealthEconomic EvaluationMedicineHealth Services ResearchHealth Care Delivery